Epidemic Expert Kang On Tackling nCoV And Science As A Leveler
Executive Summary
Gagandeep Kang of the Translational Health Science and Technology Institute and Coalition for Epidemic Preparedness Innovations talks to Scrip about early efforts to tackle nCoV-2019 and shares glimpses into her life journey in a wide-ranging interview.
You may also be interested in...
Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.